VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
Strokes are affecting approximately 1.8 million people annually
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Subscribe To Our Newsletter & Stay Updated
